Peptide bioregulation

Russian peptide bioregulators

Khavinson Vladimir Khatskelevich

Director of St.Petersburg Institute of Bioregulation and Gerontology of the North Western Dpt. of the Russian Academy of Medical Sciences

• Associate Member of the Russian Academy of Medical Sciences, professor, Doctor of Medicine

• Honored Scientist of the Russian Federation, Honored Inventor of the Russian Federation

• President of International Association of Gerontology and Geriatrics, European Region

• Vice-president of Gerontological Society of the Russian Academy of Medical Sciences

• Chief gerontologist of the Health Committee of the Government of St.Petersburg

• Member of Expert Council of the Public Chamber of the Russian Federation

• Member of Expert Council of the Higher Attestation Commission (VAK)

• The USSR Council of Ministers' Prize winner, The Ukrainian Academy of Medical Sciences Prize winner, The Ukrainian National Academy of Sciences Prize winner

• Paul Ehrlich Medal winner for outstanding achievements in preventive and social medicine, Europäische Akademie der Naturwissenschaften

• The author of over 700 scientific publications, including 27 monographs, 181 domestic and international patents

• The inventor of 6 pharmaceuticals and 39 peptide bioregulators

Quality of the products is guaranteed by the principles of qualitative manufacturing practice

"Chemico-Biological Association under the Russian Academy of Medical Sciences "Firma Vita", Ltd.

• Highly qualified specialists

• The modern system of quality control at all production stages

• "Peptide- Bio" product line is produced under the control of developer: St.Petersburg Institute of Bioregulationand Gerontology of the North Western Dpt. of the Russian Academy of Medical Sciences

CardiogenPeptide for cardiovascular system

TestagenPeptide for men’s sexual function improvement

BronchogenPeptide for bronchopulmonarysystem

NormoftalPeptide for visual organs

VesilutPeptide for urinary system

PancragenPeptide for pancreas

4

Peptide Bio product line

The composition of the latest generation of peptide bioregulators

Products are obtained by biological synthesis

• NORMOFTAL® AKS-G complex (lysine, glutamic acid)

• BRONHOGEN® AKS-B complex(alanine, glutamic acid, aspartic acid, leucine)

• KARDIOGEN® AKS-K complex(alanine, glutamic acid, aspartic acid, arginine)

• VEZILYUT® AKS-M complex(glutamic acid, aspartic acid)

• TESTAGEN® AKS-S complex(lysine, glutamic acid, aspartic acid, glycine)

• PANKRAGEN® AKS-P complex(lysine, glutamic acid, aspartic acid, tryptophan)

Epigenomic effect of peptide bioregulators

The scheme of the local separation of chains [poly(dAdT):poly(dAdT)] in consequence of binding of peptide bioregulator Ala-Glu-Asp-Gly in the major groove of a DNA double helix

Peptide bioregulators penetrate into the damaged cells, eliminate the point mutations, stimulate the restoration of the protein synthesis intensity and regulate the expression of genes responsible for cells differentiation and proliferation. As a result, in the target tissue proceed the proliferation of morphologically mature cells with the optimal metabolism level.

PEPTIDE

General action mechanism of peptide bioregulators

Damagedcell

Restoredcell

ProliferationMitosis

Protein synthesis

A complementary interaction between short peptides and DNA

Chromatin decondensation

Change in genes conformation and expression

Tissue-specific proteins synthesis

Cellular proliferation and differentiation

Regulation of biochemical and physiological processes

The cellular effects of peptide bioregulators

Mechanism of a short peptide intracellular delivery

ПЕПТИДНЫЙ БИОРЕГУЛЯТОРPEPTIDE BIOREGULATOR

Small intestine

Portal vein/liver

Cell

Target organ

The cellular effects of peptide bioregulators. Summary.

While getting into the nucleus of cells and interacting with specific chromatin loci, the PB regulate the most important steps in the genetic program implementation, such as:

• the optimal rate of stem cells division

• the maturation of low-differentiated precursor cells with the acquirement of mature cells properties

• the maintaining of an optimal range of specific enzymes and receptors in mature cells, thereby regulating their functional state

• support of non-specific protective and reparative intracellular systems activity, thereby enhancing cell viability and reducing the apoptosis rate in both normal and pathological conditions

The tissue effects of peptide bioregulators. Part 1.

• Application of peptide bioregulators allows to optimize the tissue and organic regeneration. An optimization includes:

- the support of the organ or tissue integrity in normal conditions;

- fast and effective recovery from acute or chronic effect of external damaging factors;

- significant reduction in capacity or development rate of pathological regeneration, such as fibrosis, dysplasia, metaplasia, and others

• Peptide bioregulators have a protective effect on complementary (TARGET) tissues. It leads to the increase of cells resistance under hypoxic conditions, the toxic effects and other damaging factors. This effect is associated with maintain of a high level of cellular reparative and antioxidant systems activity, and also with number of non-specific protective factors, particularly with the intracellular pool of glutathione.

The tissue effects of peptide bioregulators. Part 2.

• Peptide bioregulators normalize the tissues metabolism and maintain the optimal number and spectrum of receptors and enzymes in cells. It exerts an influence on the efficiency of nutrients assimilation in tissues and metabolic products removal. Peptide bioregulators have an effect on the complementary organs and tissues functional activity in both normal and pathological conditions.

• Peptide bioregulators maintain the metabolism and the optimal number of mature and functionally active cells. It provides the base for: 1) an effective integration of organs and tissues at the level of the entire organism under the influence of other endogenous regulatory systems; 2) an adequate functional adaptation of organs and tissues to the changing needs of the organism.

The place of the peptide bioregulatorsin the therapeutic paradigm

Contemporary therapeutic treatment regimens: combination of drug therapy, diet andrecommendations for lifestyle changes

The model of the treatment regimens development:

«Another brick in the wall» –the missing link ?

Anabolic β-blocker

Low molecularheparine

ACE inhibitor

Statine

Cardiology:For example: CHD + arterial hypertension +

hypercholesterolemia + CHF

Statins and fibrates

β-Blockers ACE inhibitors

Calcium channelblockers

Angiotensin Ireceptor antagonists

Vasodilators(В, А, А+В)

Organo-specificpeptide bioregulators

Diuretics

Central neurotropicagents

Peripheralneurotropic agents

Antiplateletagents

Anticoagulants

Pulmonology:For example: COPD

Bronchodilators: М-acetylcholine receptor

antagonists

Bronchodilators: β2-adrenergic agonists

Systemic glucocorticoids

Antibiotics

Organo-specificpeptide bioregulators

Indirectmucokinetics

Direct mucokinetics(enzymes)

Phospholipase A2 inhibitors

Fluoroquinolones

Topicalsteroids

Detoxication (tobacco, industrial poisons)

Urology:For example: andropause, spermatogenesis disorders

Organo-specificpeptide bioregulators

Hormonalreplacement therapy

Detoxication(tobacco, alcohol)

Urologicaldisorderstherapy

Nervousdisorderstherapy

Diabetestherapy

Metabolicsyndrome

therapy

Cardiovasculardiseasestherapy

PDE5inhibitors

Endocrinology:For example: the metabolic syndrome, type 2 diabetes

Biguanides(metformin)

Thiazolidinediones(pioglitazone)

Second-generation sulfonylurea medications

Secretagogues(repaglinide)

Organo-specific

peptide bioregulators

Incretinmimetics

Alpha-glucosidaseinhibitors

DIET SPORTS

B group vitamins

The main directions ofpeptide bioregulators application

Treatment:inclusion in the

treatment regimens

Post- diseaserehabilitation

Administration to healthypersons, prolongation of

the working ability period

Geroprotection +prescription to the

elderly

Peptidebioregulators

Treatment:inclusion in the

treatment regimens

Post- diseaserehabilitation

Administration to healthypersons, prolongation of

the working ability period

Geroprotection +prescription to the

elderly

Peptidebioregulators

Peptide bioregulators dosage

• The preventive dosage is one capsule two times a day. Сourse of administration is 60 days.

• Curative dosage is two capsules two times a day. Сourse of administration is from 60 to 120 days, depends on initial patient’s condition.

• Dosage recommendations may vary widely. It depends on diagnosis and method of application, such as: health improvement, prophylaxis or the inclusion in the treatment regimens.

Peptide bioregulators - 2011

• Synthesized products exclude the presence of prions and latent or active viruses exposing to risk of infectious diseases

• High purity of a substance

• Tissue-specific and organo-specific properties

• Don’t provide any stimulation or depression effects on cellular metabolism

• Hypoallergenic. No side effects

• Supplement of treatment regimen, increase of treatment effect, compatibility with all medications

• Can be taken without a prescription

• Made in Russia. Patented in 13 countries

• The absence of direct competitive products

• Bioregulatory therapy is one of the fundamental directions of pharmacology development in area of work-status longevity

Therapeutic combinations ofpeptide regulators / type 2 diabetes

Type 2diabetes

Diabetic retinopathy, autonomic neuropathy

Coronary heart disease. Peripheral vascular

atherosclerosis

Degenerative lesions of the Langerhans islets

and acinar tissue

Diabetic nephropathy + pyelonephritis

Pancragen

Normoftal

Cardiogen

Vesilut

Therapeutic combinations ofpeptide regulators / COPD

COPD

Focal atrophy of the bronchial epithelium

Cor pulmonale. Pulmonary heart

disease

Pneumosclerosis

Hypoxic damage of parenchymal organs

Bronchogen

Cardiogen

Pancragen

Therapeutic combinations ofpeptide regulators / CAD

Atherosclerosis. CAD. CHF

Cardiosclerosis

Pulmonary perfusion disturbance

Cerebrovasculardisease

Bronchogen

PancragenHypoxic damage of parenchymal organs

Normoftal

Cardiogen

Therapeutic combinations ofpeptide regulators / andropause

Andropause. BPH

Testosterone level decrease

Erectile dysfunction (with combined

genesis)

Impaired glucose tolerance

BPH.Urination disorders

Testagen

Normoftal

Pancragen

Vesilut

The benefits of peptide bioregulators

• Peptides are obtained by biological synthesis. It excludes the presence of prions, latent or active viruses and ensures a high purity of substance

• The substance is identical to the native peptide. As a result, the peptide bioregulators are hypoallergenic, safe in a wide range of doses and have no side effects

• The range of application is: health improvement, prophylaxis, monotherapy or the inclusion in the treatment regimens. It allows to create an individual dosage for each customer and patient

• Application of peptide regulators leads to a stable long-term results, increases the conventional therapy effectiveness and improves the life quality of the consumer or patient